Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 9/20 | 0.66 |
| ▸ | RARA | P10276 | 4/20 | 0.66 |
| ▸ | RARG | P13631 | 3/20 | 0.66 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | MPL | P40238 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 4/20 | 0.38 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | BRS3 | P32247 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370734 | 0.80 | RARB (1.00) | RARBRARARARGMCL1PPARD | |
| SCHEMBL4598579 | 0.80 | RARB (1.00) | RARBRARARARGMCL1PPARD | |
| SCHEMBL4190534 | 0.78 | RARB (1.00) | RARBRARARARGMCL1KDM4E | |
| SCHEMBL18624015 | 0.74 | RARB (0.64) | RARBRARARARGMCL1KDM4E | |
| SCHEMBL4196940 | 0.73 | RARB (0.58) | RARBRARARARGMCL1KDM4E | |
| SCHEMBL16609020 | 0.71 | RARB (0.70) | RARBRARARARGMCL1PPARD | |
| SCHEMBL7610607 | 0.69 | RARB (0.83) | RARBRARARARGMCL1 | |
| SCHEMBL8642272 | 0.69 | RARB (0.83) | RARBRARARARGMCL1 | |
| SCHEMBL7825340 | 0.69 | RARB (0.71) | RARBRARARARGMCL1 | |
| SCHEMBL14702289 | 0.68 | RARB (0.55) | RARBRARARARGMCL1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179317-A1 | COMBINATION THERAPY FOR HEAD AND NECK CANCER | CORNELL UNIVERSITY (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179317-A1 | COMBINATION THERAPY FOR HEAD AND NECK CANCER | RXRA, RXRB, RXRG | RARB 6/4885RARA 4/4885RARG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.